Cassady Schiller Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Cassady Schiller Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$504	Buy	+10	New	+$524	﹤0.01%	976

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Cassady Schiller Wealth Management's CORT Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Corcept Therapeutics (CORT) in Q4 2024: 10 shares worth $504. The stake represents ﹤0.01% of the portfolio and ranks #976 among its holdings.

367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

Cassady Schiller Wealth Management held 10 shares of Corcept Therapeutics worth $504 as of Q4 2024.
Corcept Therapeutics was a new Cassady Schiller Wealth Management position in Q4 2024.
Corcept Therapeutics made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #976 holding.
367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.